Results 151 to 160 of about 1,194,407 (281)
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Frontiers in PediatricsClinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown high overall response rates in patients with relapsed/refractory B-cell malignancies.
Shuto Negishi +10 more
doaj +1 more source
CAR-T cell therapy for cancer: current challenges and future directions
Signal Transduction and Targeted TherapyChimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells.
I. Zugasti +9 more
semanticscholar +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin +4 more
wiley +1 more source
Production system establishment and in vitro study of CD19/CD3ε bite antibody secreted from Pichia pastoris [PDF]
Blinatumomab is an anti-cancer Bispecific T-cell Engager (BiTE) antibody drug approved by the Food and Drug Administration (FDA) for treating acute lymphoblastic leukemia (ALL).
Boram Kim +4 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used by solid organ transplant recipients. Although it is known that MMF suppresses immune responses, its exact effects on specific vaccinations have not been investigated yet. Mucosal vaccinations are increasingly used, such as a cholera vaccination consisting of two oral immunizations ...
Boukje C. Eveleens Maarse +4 more
wiley +1 more source
Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance [PDF]
, 1993 A portion of patients with acute myeloid leukemia also display surface antigens associated with lymphoid development (Ly+AML). The incidence of Ly+AML varies considerably between independent studies, both overall and with regard to individual antigens ...
Thiel, E., Drexler, H.G., Ludwig, W.D.
core
CAR-T cells targeting CD19 for the treatment of ANCA vasculitis [PDF]
Autoimmune ANCA-associated vasculitis (AAV) and glomerulonephritis is characterized by the presence of autoantibodies (so-called ANCA = anti-neutrophil cytoplasmic autoantibodies), which, by binding to the body's own antigens, lead to damaged blood ...
Schreiber, Adrian, Lodka, Dörte
core +1 more source